Spinocerebellar ataxia type 36 (SCA36),^[@R1],[@R2]^ identified in 2011 as a novel subtype of SCA, is caused by the expansion of a typically large GGCCTG hexanucleotide repeat (650--2,500) in the nucleolar protein 56 gene (*NOP56*). Unlike other CAG repeat disorders resulting in polyglutamine protein aggregation, SCA36 is an RNA-mediated neurodegenerative disorder attributable to RNA toxic gain of function.^[@R3]^ Other noncoding repeat expansion disorders include fragile X tremor ataxia syndrome, SCA8, SCA10, SCA31, and amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) with the *C9orf72* GGGGCC repeat expansion. There are few reports about SCA36; most are about populations in Japan, Spain, and France.^[@R1],[@R2],[@R4][@R5][@R6]^

SCA36 is a slowly progressive cerebellar ataxia similar to other late-onset ataxias, such as SCA6, SCA23, and SCA35.^[@R7][@R8][@R11]^ Although the most distinguishing feature of SCA36 is lower motor neuron involvement, discrepancies in clinical phenotypes have been reported. For example, atrophy and fasciculation of the tongue and limb muscles are present in 12% of French patients in contrast to 63% of Japanese patients.^[@R5]^ As both cerebellar ataxia and lower motor neuron involvement are important features of SCA36, it would be intriguing to investigate whether the hexanucleotide repeat expansion in *NOP56* is present in patients with apparently sporadic ataxia or ALS. In the present study, we aimed to identify SCA36 mutations primarily in patients with hereditary ataxias and, secondarily, in healthy controls, and individuals with sporadic ataxia syndromes and those with ALS. Furthermore, we quantified the expression of microRNA-1292 and 7 target genes to evaluate their role in SCA36 pathogenesis.^[@R1]^

METHODS {#s1}
=======

Participants. {#s1-1}
-------------

We recruited all study participants from the Neurology Clinic of Taipei Veterans General Hospital. First, we surveyed for hexanucleotide repeat expansion in intron 1 of *NOP56* in 109 molecularly unassigned index patients from 512 SCA pedigrees, after mutations responsible for SCA1, 2, 3, 6, 7, 8, 10, 12, 17, 19/22, 23, 26, 27, 28, 31, and 35 and dentatorubral-pallidoluysian atrophy were excluded. We tentatively diagnosed SCA (i.e., inherited cerebellar ataxia, including autosomal-dominant and autosomal-recessive ataxia) according to the Harding diagnostic criteria^[@R12]^ and a "positive" family history, defined as the probands having at least one first- or second-degree relative with a clinical history of ataxia. We enrolled 21 individuals from the 3 SCA36 families, including 7 affected patients, 4 individuals with uncertain phenotypes, 8 unaffected individuals, and 2 spouses. In addition, we studied 502 patients with sporadic ataxia syndromes (including early-onset cerebellar ataxia and multiple system atrophy), 144 patients with ALS, and 323 healthy controls. We diagnosed ALS according to the revised El Escorial World Federation of Neurology criteria.^[@R13]^ All participants were of Han Chinese descent. All participants gave written informed consent before participating in the study. The Institutional Review Board of the Taipei Veterans General Hospital approved the study protocol (TPVGH IRB 2014-03-006A).

Clinical investigations. {#s1-2}
------------------------

We defined age at onset as the age at which the earliest symptoms occurred according to statements given by patients or their caregivers and scored clinical severity of ataxia using the 40-point (0 being normal) validated Scale for the Assessment and Rating of Ataxia (SARA).^[@R14],[@R15]^ Study participants underwent brain MRI and magnetic resonance spectroscopy (MRS) in a 1.5-T system (Signa EXCITE, GE Medical Systems, Milwaukee, WI). For MRS, we calculated peak areas for N-acetylaspartate (NAA) at 2.02 parts per million (ppm), creatinine (Cr) at 3.03 ppm, and the metabolite intensity ratio (NAA/Cr ratio) of both cerebellar hemispheres and vermis using FuncTool software (GE Healthcare, Milwaukee, WI).^[@R16],[@R17]^ We also conducted nerve conduction studies (NCS) and EMG and pure tone audiometry^[@R18]^ of air conduction hearing thresholds at 4 frequencies (500, 1,000, 2,000, and 4,000 Hz) using a calibrated diagnostic audiometer and evaluated somatosensory evoked potentials (SSEPs).

We conducted a global cognitive performance assessment using the Mini-Mental State Examination^[@R19]^ (MMSE, score range 0--30), one of the most widely used screening instruments for cortical dementia, and Montreal Cognitive Assessment^[@R20]^ (MoCA, score range 0--30). Frontal lobe executive function was evaluated using the Frontal Assessment Battery (FAB, score range 0--18).^[@R21]^

Mutation screening. {#s1-3}
-------------------

We isolated the genomic DNA from peripheral blood leukocytes and ascertained the presence of the GGCCTG hexanucleotide repeat expansion in *NOP56* using repeat-primed PCR as described previously.^[@R1]^ The amplicons generated by the repeat-primed PCR from an allele with an expanded repeat gave rise to a characteristic saw tooth pattern with a 6-bp periodicity on the electropherogram ([figure 1A](#F1){ref-type="fig"}). We conducted fragment length analysis on an ABI Prism 3700 Genetic Analyzer (Applied Biosystems, Waltham, MA) to determine the repeat count in alleles with a short hexanucleotide repeat (\<40 units).^[@R5]^ Primer sequences are detailed in table e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000068).

![Detection of *NOP56* hexanucleotide repeat expansions\
(A) Attenuating peaks of nucleolar protein 56 gene (*NOP56*) (GGCCTG)n expansions by repeat-primed PCR in a patient with SCA36 (upper panel) and normal features in a healthy control (lower panel); (B) Fragment length analysis: a single peak indicates either the presence of 2 homozygous alleles of short hexanucleotide repeats or 1 short hexanucleotide repeat and a large repeat expansion (\>650 repeats) that failed to be amplified (upper panel), whereas 2 different peaks indicate the presence of 2 normal heterozygous alleles (lower panel). (C) Hexanucleotide repeat counts in healthy controls, patients with sporadic ataxic syndromes, and those with ALS in this study. ALS = amyotrophic lateral sclerosis.](NG2015000976FF1){#F1}

Haplotype analyses. {#s1-4}
-------------------

We genotyped 8 microsatellite markers and 17 single nucleotide polymorphisms (SNPs) flanking the *NOP56* (GGCCTG)n repeat covering 1.8 Mb in 21 family members from the 3 Chinese SCA36 pedigrees (tables e-1 and e-2). We used HAPLORE software for haplotype inferences.^[@R22]^

Lymphoblastoid cell lines. {#s1-5}
--------------------------

We cultured Epstein-Barr virus--transformed human lymphoblastoid cell lines (LCLs) from 5 patients with SCA36 (II-4 from pedigree A; II-1, II-3, and II-4 from pedigree B; and II-1 from pedigree C) and 5 sex- and ethnicity-matched healthy controls following a standard protocol.^[@R23]^ LCLs were cultured in RPMI-1640 medium (ATCC, Manassas, VA) supplemented with 20% fetal bovine serum (Invitrogen, Carlsbad, CA) and 100 U/mL of penicillin/streptomycin.

Quantitative real-time PCR for microRNA-1292 and target genes. {#s1-6}
--------------------------------------------------------------

We partitioned microRNA-1292 from the extracted total RNA by reverse transcription using a TaqMan microRNA reverse transcription kit (Applied Biosystems) and performed quantitative real-time PCR (qPCR) using TaqMan microRNA assays with normalization to RNA-U6B (Applied Biosystems) in an ABI7500 real-time PCR machine (Applied Biosystems).

Using TargetScan 6.2 (<http://targetscan.org/>), we predicted 7 genes (*SRSF6*, *FUS*, *SPG7*, *ITPKA*, *GRIK3*, *GRIN2B*, and *GAD2*) to be target genes of microRNA-1292 (table e-3). Relative expression of each target gene was determined in LCLs using qPCR with specific primers (table e-1). We calculated expression ratios as the normalized threshold cycle (Ct) value difference with the adjustment for the amplification efficiency relative to glyceraldehyde-3-phosphate dehydrogenase.

Statistical analyses. {#s1-7}
---------------------

For cellular studies, we present variables as mean ± SEM from 3 independent experiments. The Student *t* test compares the expression of microRNA-1292 and its target genes between controls and patients with SCA36. Analysis of variance (ANOVA) compares the hexanucleotide repeat counts of *NOP56* in the controls, patients with sporadic ataxic syndromes, and those with ALS. A 2-sided *p* value \<0.05 is considered significant.

RESULTS {#s2}
=======

Identification of hexanucleotide repeat expansion in *NOP56*. {#s2-1}
-------------------------------------------------------------

We identified hexanucleotide repeat expansion in *NOP56* in 3 index cases from the 109 probands with molecularly unassigned SCA among the 512 pedigrees ([figure 1A](#F1){ref-type="fig"}). Therefore, SCA36 accounted for 0.6% (3/512) of SCA in the Han Chinese in this study.

Because short hexanucleotide repeat expansion (15--40 units) has been recently described in a few patients with SCA36,^[@R5]^ we conducted fragment length analysis to determine the repeat length of alleles with short *NOP56* hexanucleotide repeat expansions ([figure 1B](#F1){ref-type="fig"}). We did not observe *NOP56* (GGCCTG)n expansion in the 323 controls, 502 patients with sporadic ataxia syndromes, or 144 patients with ALS. None carried a *NOP56* (GGCCTG)n repeat with a size exceeding the threshold of 14 units ([figure 1C](#F1){ref-type="fig"}). There was no difference in the distribution of the *NOP56* hexanucleotide repeat lengths among healthy controls, patients with sporadic ataxia syndromes, and those with ALS (7.86 ± 1.61, 7.91 ± 1.52, and 7.88 ± 1.58, respectively, ANOVA *p* = 0.81).

Clinical characteristics. {#s2-2}
-------------------------

Repeat-primed PCR resulted in the identification of expanded *NOP56* GGCCTG hexanucleotide repeats in 11 individuals from 3 pedigrees with an autosomal-dominant ataxic syndrome ([figure 2](#F2){ref-type="fig"}). We clinically evaluated 5 of the 7 patients with ataxic symptoms; the average age at onset was 44.8 ± 3.8 years (mean ± SD; range 43--50; [table 1](#T1){ref-type="table"}). The phenotypes of 4 other individuals with expanded GGCCTG repeats in *NOP56* were not accessible (II-7, III-1, and III-3 from pedigree A and III-1 from pedigree B).

![Pedigrees and haplotype analyses of the 3 Chinese spinocerebellar ataxia type 36 families\
Haplotype analyses of representative microsatellite/single nucleotide polymorphism markers flanking the nucleolar protein 56 gene (*NOP56*). The common haplotype shared by all 3 families is marked with a black rectangle, and the common haplotype shared among the members of an individual family is shaded with gray color. Open symbol: unaffected; filled symbol: affected and symptomatic; gray symbol: individuals with uncertain phenotypes; symbol with a diagonal line: deceased; arrow: proband. I = insertion; D = deletion.](NG2015000976FF2){#F2}

###### 

Clinical characteristics of patients with spinocerebellar ataxia type 36 in the literature and from the present study

![](NG2015000976TT1)

The index case of pedigree A (II-4) initially presented with dizziness, clumsy hands, and progressive gait unsteadiness at the age of 47 years. He also experienced dysarthria, tendency to choking, and diplopia as the disease advanced, along with hearing impairment, muscle atrophy in the thighs, and leg muscle cramps. On examination at age 63, the patient had saccadic pursuits, ataxic dysarthria, limb dysmetria, generalized hyperreflexia, brisk jaw jerk, glabellar reflex, and Babinski signs. He was barely able to stand without assistance. Limb ataxia remained mild with preserved handwriting. The patient also had atrophy and fasciculation in the tongue, quadriceps, and hamstrings and impaired vibration sense in the toes. He had no bradykinesia, hand tremor, or other parkinsonism features and had preserved pinprick, light touch, and proprioception. He had EMG features of reduced recruitment and the presence of giant motor unit potentials. Over a 10-year period, the patient\'s amplitudes of sensory action potentials (SAPs) of the sural nerves gradually decreased (10.4 and 12.4 μV at age 53; 6.2 and 6.3 μV at age 63), suggesting progressive mild-to-moderate sensory polyneuropathy. Progressive hearing impairment began at age 60, with an average hearing threshold of 40 db in the left ear and 32.5 db in the right ear at age 63. His SARA score was 21 fifteen years after disease onset and 2 points worse 1 year later. The patient had normal cognitive function with an MMSE score of 28 but mildly impaired frontal executive function (FAB score = 12). Brain MRI revealed diffuse cerebellar atrophy and mild atrophy of the cerebral cortices ([figure 3, A and B](#F3){ref-type="fig"}). MRS 16 years after onset featured an impaired biochemical profile in the cerebellar hemispheres and vermis with an NAA/Cr ratio of 0.77 and 0.74 in comparison with 1.0 ± 0.13 and 0.9 ± 0.11 in healthy controls.^[@R16],[@R17]^

![Features of T1-weighted brain MRI in patients with spinocerebellar ataxia type 36\
Patient II-4 in pedigree A with disease duration of 6 years (A) and 16 years (B). Patient II-1 in pedigree C with disease duration of 4 years (C) and 7 years (D).](NG2015000976FF3){#F3}

Patient II-4 of pedigree B showed progressive gait difficulties and slurred speech and choked easily since age 44. On examination at age 52, he had impaired ocular pursuits, increased muscle tone, generalized hyperreflexia, and lower limb muscle atrophy. His NCS and SSEPs were within normal ranges. The patient\'s family history was remarkable for 1 elder brother, 1 elder sister, and 1 younger sister with similar ataxic symptoms ([figure 2](#F2){ref-type="fig"}, [table 1](#T1){ref-type="table"}). The common features of patients with ataxic symptoms (II-1, II-3, and II-4) in this pedigree included truncal ataxia, saccadic pursuits, ataxic dysarthria, dysphagia, hearing impairment, increased muscle tone, and generalized hyperreflexia. Leg muscle cramps were a frequent complaint. We did not observe tongue atrophy or fasciculation or cognitive dysfunction on examination.

The clinical course and manifestations of patient II-1 from pedigree C resembled the affected patients from pedigrees A and B ([table 1](#T1){ref-type="table"}). This patient\'s initial clinical features were progressively unsteady gait and a propensity to fall, since age 50 years. Seven years after disease onset, she was unable to stand or walk in tandem and had subtly impaired hand coordination. The patient had fragmented pursuits, mild dysarthria, postural hand tremors, generalized hyperreflexia, and absent Babinski sign. We did not observe tongue or limb atrophy or fasciculation. The patient reported subtle impairment of vibration sense on the toes with mild sensory neuropathy on NCS (sural SAPs = 11.8 and 9.8 μV at age 57). Tinnitus and subjective hearing impairment occurred at age 55, and she had mildly impaired hearing at age 57 (hearing threshold of 32.5 db at 4,000 Hz). This patient had a SARA score of 9.5, 4 years after disease onset and 13.5, 3 years later. Her memory and cognition (MMSE score = 30, MoCA score = 28) seemed normal, but executive function (FAB score = 14) was marginal. Brain MRI results showed diffuse cerebellar atrophy with preserved cerebral and brainstem structures ([figure 3, C and D](#F3){ref-type="fig"}). MRS featured mildly reduced NAA/Cr ratios in the cerebellar hemispheres and vermis (0.80 and 0.84, respectively). The patient\'s father (I-1 of pedigree C) began to manifest progressive gait unsteadiness and tendency to fall at age 58. His report showed diplopia, easy choking, muscle atrophy in the thighs, and hearing impairment toward the end of his life.

Haplotype studies. {#s2-3}
------------------

We conducted haplotype studies in 21 individuals from the 3 pedigrees, including 7 patients, 4 individuals with uncertain phenotypes, 8 unaffected individuals, and 2 spouses ([figure 2](#F2){ref-type="fig"}). Families A and B shared a common haplotype between loci rs1015159 and D20S198, which delimited a 48-kb region flanking the (GGCCTG)n expansion. Families A, B, and C shared the same haplotype within a smaller region of 5.3 kb (rs2073196 to rs6753) ([figure 2](#F2){ref-type="fig"} and table e-2).

MicroRNA-1292 and its target genes. {#s2-4}
-----------------------------------

We observed reduced microRNA-1292 expression levels (63%) in 5 patients with SCA36 compared with 5 healthy controls (0.37 ± 0.09 vs 1.08 ± 0.21, *p* = 0.01; figure e-1). In silico prediction suggested that *SRSF6*, *FUS*, *SPG7*, *ITPKA*, *GRIK3*, *GRINB2*, and *GAD2* were potential targets of microRNA-1292 (table e-3). Four genes (*SRSF6*, *FUS*, *SPG7*, and *ITPKA*) had unaltered expression for patients with SCA36 and healthy controls; 3 genes (*GRIK3*, *GRINB2*, and *GAD2*) were not measureable in LCLs (figure e-1).

DISCUSSION {#s3}
==========

After characterizing the clinical features of 5 patients with SCA36 from 3 Chinese pedigrees, our data indicate that SCA36 accounts for only a small percentage (0.6%) of SCAs among the Han Chinese. Prevalence is much lower than that reported in Galicia, Spain (6.3%), Okayama, Japan (3.6%), France (1.9%), or metropolitan Tokyo, Japan (1.5%).^[@R1],[@R2],[@R4],[@R5]^

The phenotypes of SCA36 are quite homogeneous across different ethnic groups. Common features include truncal ataxia as the initial and most prominent symptom, followed by mild appendicular ataxia, ataxic dysarthria, saccadic pursuits, and generalized hyperreflexia with or without Babinski sign ([table 1](#T1){ref-type="table"}). Hearing impairment is also a distinguishing feature, present in three-fourths of SCA36 patients in Taiwan, Japan, and Spain (74%--88%) and less frequently in France (44%).^[@R1],[@R2],[@R4],[@R5]^ Hearing is remarkably impaired at high frequencies and hearing defects correlate with disease duration and SARA scores,^[@R24]^ suggesting a link between sensorineural hearing loss and SCA36 pathogenesis. In contrast to the much higher percentage (61%--71%) noted in initial reports, we observed tongue atrophy and fasciculation in only 20% of cases in this study (12% in France^[@R5]^ and 25% in Japan^[@R6]^; [table 1](#T1){ref-type="table"}).^[@R1],[@R2]^ Because lower motor neuron involvement is more frequently reported in patients with a prolonged disease course, it might not be appropriate to regard such involvement as a prerequisite for clinical diagnosis of SCA36. Thorough cognitive assessment in 2 of our patients revealed mildly impaired executive function without defects in other cognitive domains. One report described a SPECT imaging study in patients with SCA36, which showed reduced cerebral blood flow in the inferior frontal, dorsolateral prefrontal, and ventral frontal cingulate gyri,^[@R25]^ implicating an anatomical basis for the cognitive impairment. Because a GGGGCC hexanucleotide repeat expansion in *C9orf72* is an important cause of both ALS and FTD,^[@R26]^ it would be intriguing to learn whether an *NOP56* GGCCTG hexanucleotide repeat expansion also affects cognitive function by sharing similar molecular underpinnings.

The pathogenic mechanism underlying hexanucleotide repeat expansion in intron 1 of *NOP56* remains to be elucidated. Abnormal expansion of short segment repeats in noncoding regions may cause RNA-mediated toxicity, including aberrant transcription at mRNA splicing and processing, sequestration of mRNA-associated protein complex, translation silencing by antisense transcripts, and repeat-associated non-ATG translation.^[@R3],[@R27],[@R28]^ Typically, these noncoding RNA expansion diseases are caused by hundreds to thousands of repeat unit expansions, as seen in myotonic dystrophy 1 (approximately mean 650 repeats for classic form),^[@R29],[@R30]^ SCA10 (800--4,500 repeats),^[@R31],[@R32]^ SCA31 (2.5--3.8 kb insertion),^[@R33],[@R34]^ and ALS/FTD caused by the *C9orf72* repeat expansion (400--4,400 repeats are unambiguously pathogenic).^[@R35]^ For SCA36, expanded repeat alleles ranging from approximately 650 to 2,500 repeats were considered typically pathogenic,^[@R1],[@R2]^ although a recent study found that (GGCCTG)n repeats of 25--31 units might also contribute to ataxic symptoms in SCA36 pedigrees.^[@R5]^ In this study, none of the 969 non-SCA individuals (controls, patients with sporadic ataxia, and those with ALS) have an *NOP56* hexanucleotide repeat longer than 14 units.

The gene encoding microRNA-1292 is located 19 bp downstream of the *NOP56* (GGCCTG)n repeat and, therefore, perturbed microRNA-1292 expression has been implicated in SCA36 pathogenesis.^[@R1]^ In agreement with the literature, we observed reduced expression of microRNA-1292 in LCLs of our SCA36 patients compared with the controls. Current data, however, were insufficient to support a regulatory role for microRNA-1292 in the predicted target genes. It is possible that microRNA-1292 expression is simply an epiphenomenon of abnormal (GGCCTG)n expansion and might not play an active role in disease pathogenesis. Three microRNA-1292 target genes (*GRIK3*, *GRINB2*, and *GAD2*) were not measureable in LCLs. Arguably, LCLs may not be an appropriate platform to study SCA36 pathogenesis because such cell lines might not faithfully recapitulate the pathologic phenotypes of Purkinje cells.

Han Chinese individuals carrying the expanded SCA36 hexanucleotide repeats might have originated from the same ancestor. The 3 SCA36 pedigrees in this study shared a common haplotype spanning from loci rs2073196 to rs6753 ([figure 2](#F2){ref-type="fig"}). It is of interest to note that the haplotype that comprised 7 SNP markers in a 1.3-kb region flanking the *NOP56* hexanucleotide repeats (rs2073196 to rs78833048) was identical among the French, Japanese, and Taiwanese patients with SCA36.^[@R5]^

In conclusion, SCA36 is a rare subtype of SCAs in the Han Chinese population. In patients with late-onset SCA and a protracted course, lower motor neuron signs in the limbs and tongue might suggest the possibility of SCA36. Impaired hearing and executive function might be other diagnostic clues, but this needs further verification.
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